CD8A and neoplasm: Similarly, inhibiting mTORC1 via rapamycin or blocking AR/EGFR signaling using Gefitinib enhanced anti-tumor CD8+ T-cell functions, highlighting the importance of Treg-driven processes in HCC TME (51).